1. Academic Validation
  2. Sevelamer

Sevelamer

  • Nephron Clin Pract. 2003;94(3):c53-8. doi: 10.1159/000072021.
Jane Henderson 1 Paul Altmann
Affiliations

Affiliation

  • 1 Oxford Kidney Unit, Churchill Hospital, Oxford, UK.
Abstract

Hyperphosphataemia in patients with chronic renal failure has traditionally been treated with calcium- and aluminium-containing phosphate Binders. This article briefly discusses the rationale and complications of these treatments and reviews sevelamer that is a novel non-calcium-, non-aluminium-containing phosphate binder and the evidence to support its use in clinical practice.

Figures
Products